The Tarceva Italian Lung Optimization Trial (TAILOR) was a randomize phase III trial that compared erlotinib and docetaxel as second-line treatment of patients with advanced NSCLC with wild-type EGFR [17]. Here, EGFR is linked to non-small cell lung carcinoma.